Biomarkers of RCC, such as VHL, TP53/p53, KRAS, AKT, XIAP, MCL-1, TGase 2, MDM2, HIF1α, NRF2, and HIF2α, have been identified as key indicators for the diagnosis, prognosis, and treatment of RCC [12]. This evidence concerns the gene MDM2 and renal cell adenocarcinoma.